Fallopian tube cancer

Active Research Protocols

  1. 04-C-0232 – A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
  2. 07-C-0058 – A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
  3. 07-C-0061 – Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the VEGFR2 Inhibitor, ZD6474 (Vandetanib) in Women with Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  4. 11-C-0022 – A Pharmacokinetic/Pharmacodynamic Study with a Phase I Run-In with a PARP Inhibitor (Olaparib) in Combination with Carboplatin for Refractory or Recurrent Women's Cancers
  5. 11-C-0033 – Extended Follow-up of High Ovarian Cancer Risk Cohort from 02-C-0268 (GOG-199)
  6. 11-C-0061 – Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
  7. 11-C-0080 – Ph II Randomized Trial of the Combination of ABT-888 with Metronomic Oral Cyclophosphamide in Refractory BRCA-Pos Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Neg Breast Cancer, and Low-Grade NHL
  8. 12-C-0081 – Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
  9. 12-C-0191 – Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
  10. 13-C-0036 – A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014